Kura Oncology, Inc. (FRA:KUR)

Germany flag Germany · Delayed Price · Currency is EUR
6.96
-0.12 (-1.67%)
Last updated: Jan 28, 2026, 8:02 AM CET
-5.25%
Market Cap594.73M +8.7%
Revenue (ttm)88.66M
Net Income-184.85M
EPS-2.11
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume513
Open6.96
Previous Close7.08
Day's Range6.96 - 6.96
52-Week Range4.68 - 10.78
Betan/a
RSI34.22
Earnings DateFeb 26, 2026

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Troy Wilson
Employees 192
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol KUR
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements